Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.

MLA

Landre, Thierry, et al. “Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.” Drugs & Aging, vol. 37, no. 10, Oct. 2020, pp. 747–54. EBSCOhost, https://doi.org/10.1007/s40266-020-00788-5.

APA

Landre, T., Des Guetz, G., Chouahnia, K., Fossey-Diaz, V., & Culine, S. (2020). Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. Drugs & Aging, 37(10), 747–754. https://doi.org/10.1007/s40266-020-00788-5

Chicago

Landre, Thierry, Gaetan Des Guetz, Kader Chouahnia, Virginie Fossey-Diaz, and Stéphane Culine. 2020. “Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.” Drugs & Aging 37 (10): 747–54. doi:10.1007/s40266-020-00788-5.